American Journal of Biomedical Research
ISSN (Print): 2328-3947 ISSN (Online): 2328-3955 Website: http://www.sciepub.com/journal/ajbr Editor-in-chief: Hari K. Koul
Open Access
Journal Browser
Go
American Journal of Biomedical Research. 2019, 7(2), 38-43
DOI: 10.12691/ajbr-7-2-3
Open AccessArticle

Evaluation of the Factors Associated with Lipid Metabolism and the Response to Treatment in Type 2 Diabetic Patients Monitored at CHD-Atacora (Benin)

Tinéponanti B.T. Véronique1, 2, Chabi Nicodème Worou1, 3, , Sognigbé G. Basile1, 4, Adam Alassane2, Akpovi D. Casimir3, Sina Haziz4, Kohonou N. Arnaud1, 4 and Baba-Moussa Lamine4

1Laboratoire de Biochimie et de Biologie Moléculaire, Department de Biochimie et de Biologie Cellulaire, Faculté des Sciences et Techniques, Université d’Abomey-Calavi, Bénin

2Service de diabètologie, Centre Hospitalier Départemental de l’Atacora, Bénin

3Laboratoire de Recherche en Biologie Appliquée, Ecole Polytechnique d’Abomey-Calvi, Université d’Abomey-Calavi, Bénin

4Laboratoire de Biologie et de Typage Moléculaire en Microbiologie, Département de Biochimie et de Biologie Cellulaire, Faculté des Sciences et Techniques, Université d’Abomey-Calavi, Bénin

Pub. Date: December 17, 2019

Cite this paper:
Tinéponanti B.T. Véronique, Chabi Nicodème Worou, Sognigbé G. Basile, Adam Alassane, Akpovi D. Casimir, Sina Haziz, Kohonou N. Arnaud and Baba-Moussa Lamine. Evaluation of the Factors Associated with Lipid Metabolism and the Response to Treatment in Type 2 Diabetic Patients Monitored at CHD-Atacora (Benin). American Journal of Biomedical Research. 2019; 7(2):38-43. doi: 10.12691/ajbr-7-2-3

Abstract

Non-insulin-dependent diabetes mellitus (NIDDM) is a multifactorial disease resulting from the interaction of genetic and environmental factors. The aim of this study was to evaluate the factors associated with lipid metabolism and treatment response in type 2 diabetic patients monitored at CHD-Atacora (Benin). A total of 200 diabetic patients were included in the study. 121 women and 79 men into two groups; namely 132 had hyperglycemia and 68 in normoglycemia. Diabetics had a mean BMI of 27.95 kg / m2 while normoglycemic subjects had a BMI of 24.84 kg / m2. In addition, diabetic subjects had an average triglyceride level of 2.28 mmol / L whereas subjects with normoglycemia had an average triglyceride level of 1.04 mmol / L. Oral antibiotics did not have a significant effect on lipid metabolism and glycemic control. Eating habits were similar in both groups and did not respond to a balanced diet. The results of our study reveal that triglyceride levels and BMI are a factor influencing the glycemic status of diabetic subjects. Low levels of BMI and triglyceride levels promote good glycemic control in diabetic patients monitored in the diabetic department of CHD-Atacora.

Keywords:
type 2 diabetes dyslipidemia metformin glibenclamide Atacora Benin

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mel-litus: problems and prospects. Endocrine Rev 1998; 19: 477-90.
 
[2]  DeFronzo. R.A. 2004. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 88:787-835. ix.
 
[3]  Subramanian S. Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta. 2012; 1821(5): 819-825. 15.
 
[4]  Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997; 38(11): 2173-2192.
 
[5]  Miller M. Stone NJ. Ballantyne C. Bittner V. Criqui MH. Ginsberg HN. Goldberg AC. Howard WJ. Jacobson MS. Kris-Etherton PM. Lennie TA. Levi M. Mazzone T. Pennathur S; American Heart Association Clinical Lipidology. Thrombosis. and Prevention Committee of the Council on Nutrition. Physical Activity. and Metabolism Council on Arteriosclerosis. Thrombosis and Vascular Biology Council on Cardiovascular Nursing Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123(20): 2292-2333.
 
[6]  Ferriéres J. Bongard V. Dallongeville J. Trens in plasma lipids. lipoproteins and dyslipidemias in French adults. 1996-2007. Arch Cardiovasc Dis 2009; 102 (4): 239-301.
 
[7]  Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009; 5: 150-159.
 
[8]  WHO Expert Committee on the Selection and Use of Essential Medicines (‎2010: Geneva, Switzerland)‎ & World Health Organization. (‎2010)‎. Liste modèle de l'OMS des médicaments essentiels : 16e liste - révision mars 2010. Genève : Organisation mondiale de la Santé. https://apps.who.int/iris/handle/10665/70644.
 
[9]  Amélie et al.. 2007. Traitement médicamenteux du diabète de type 2 (première partie). La Presse Médicale 36(2). 269-278. 2007.
 
[10]  Collier CA. Bruce CR. Smith AC. Lopaschuk G. Dyck DJ. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am J Physiol Endocrinol Metab. 2006; 291(1): E182-E189.
 
[11]  Bories T. 2012. Prise en charge thérapeutique des patients diabétiques de type 2 par les médecins généralistes de l’Eure. Médecine humaine et pathologie. 2012. Thèse pour le doctorat en Médecine 35p.
 
[12]  Krentz AJ. Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005; 65(3): 385-411.
 
[13]  Bolen S, Wilson L, Vassy J, Feldman L, Yeh J, Marinopoulos S, Wilson R, Cheng D, Wiley C, Selvin E, Malaka D, Akpala C, Brancati F, and Bass E (2007) Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes, Agency for Healthcare Research and Quality (US), Rockville (MD).
 
[14]  CEED 2013: Le Centre Européen d’étude du Diabète Hiver lettre n°6. 9.
 
[15]  Blaak E. Sex differences in the control of glucose homeostasis. Curr.Opin.Clin.Nutr.Metab Care. 2008; 11: 500-504.
 
[16]  Eticha T, Mulu A, Gebretsadik H, Kahsay G, Ali DYR. Factors associated with poor glycemic control in type 2 diabetic patients investigated at Ayder Referral Hospital, Mekelle, Ethiopia. Ijppr Human. 2016; 6(3): 160-171.
 
[17]  Kassahun T, Eshetie T, and Gesesew H (2016a). Factors associated with glycemic control among adult patients with type 2 diabetes mellitus: a cross-sectional survey in Ethiopia. BMC Res Notes 9: 78.
 
[18]  Gomis R, Artola S, Conthe P, Vidal J, Casamor R, and Font B (2014a). [Prevalence of type 2 diabetes mellitus in overweight or obese outpatients in Spain. OBEDIA Study]. Med Clin (Barc) 142: 485-492.
 
[19]  Liu L, Yin X, and Morrissey S (2012) Global variability in diabetes mellitus and its association with body weight and primary healthcare support in 49 low- and middle-income developing countries. Diabet Med 29: 995-1002.
 
[20]  Kannel W. Gordon T. Castelli W. Obesity. lipids. and glucose intolerance. The Framingham Study. Atherosclerosis. 1993; 102(1): 63-67.
 
[21]  Yonas Mullugeta. Rajinder Chawla. Kebede T . Yesehak Worku Dyslipidemia Associated with Poor Glycemic Control in Type 2 Diabetes Mellitus and the Protective Effect of Metformin Supplementation.Indian J Clin Biochem. 2012.
 
[22]  Abdel-Gayoum AG. The effect of glycemic control in type 2 diabetic patients with diabetes-related dyslipidemia. Saudi Med J. 2004; 25(2): 207-211.
 
[23]  Guerci B. Böhme P. Kearney-Schwartz A. Zannad F. Drouin P. Endothelial dysfunction and type 2 diabetes: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab (Paris). 2001; 27: 436-447.
 
[24]  Hirano T, Mamo JC, Furukawa S, Nagano S, Takahashi T. Effect of acute hyperglycemia on plasma triglyceride concentration and triglyceride secretion rate in non fasted rats. Diabetes Res Clin Pract. 1990; 9(3): 31-38.
 
[25]  U.K. Prospective Diabetes Study. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997; 20: 1683-1687.
 
[26]  Mohammadi H. Abdelouahed E-M. Hassar M. Bouchrif B. Qarbal B. Dahbi F. Hilal L. Ghalim N. Glycaemic control. HbA1c. and lipid profile in children with type 1 diabetes mellitus. Eur J Sci Res. 2009; 29(2): 289-294.
 
[27]  Srivastava V. Sarkar S. Jena J. and Mohanty M. Analysis of therapeutic outcome of antidiabetic medications in a tertiary care Hospital-an Observational study. Journal of Diabetes and Metabolism 2017.
 
[28]  (OMS). O.M.d.l.S.. Rapport Mondial sur le diabète. Genève. 2016. OMS: p. 4.
 
[29]  Belfort. R.. L. Mandarino. S. Kashyap. K. Wirfel. T. Pratipanawatr. R. Berria. R.A. Defronzo. and K. Cusi. 2005. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes. 54: 1640-8.
 
[30]  Houinato. D.. J. Segnon. F. Djrolo. and O. Djigbennoude. 2008. 'Rapport final de l'enquête STEPS au Benin'. PNL/MNT: 10-126.